Free tool
FAERS Monitor: Myhibbin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216482 or its brand name (Myhibbin, Mycophenolate Mofetil). Reports on generic versions are filed under their own applications.
Reports
106,242
Serious
99,414
94% of reports
Hospitalization
39,174
Death reported
20,488
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use16,486
- drug ineffective10,406
- product use in unapproved indication7,029
- diarrhoea5,216
- pyrexia4,594
- cytomegalovirus infection4,470
- pneumonia4,405
- condition aggravated3,948
- transplant rejection3,569
- infection3,508
- fatigue3,430
- nausea3,309
- vomiting3,101
- acute kidney injury3,099
- dyspnoea3,084
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 264 |
| 2005 | 312 |
| 2006 | 586 |
| 2007 | 750 |
| 2008 | 1,013 |
| 2009 | 1,546 |
| 2010 | 1,368 |
| 2011 | 1,579 |
| 2012 | 1,528 |
| 2013 | 1,511 |
| 2014 | 1,774 |
| 2015 | 2,127 |
| 2016 | 2,666 |
| 2017 | 4,368 |
| 2018 | 6,301 |
| 2019 | 8,404 |
| 2020 | 9,582 |
| 2021 | 9,117 |
| 2022 | 8,343 |
| 2023 | 9,669 |
| 2024 | 12,352 |
| 2025 | 12,320 |
| 2026 | 8,757 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,947,917 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| transplant rejectionSignal | 3,569 | 158.0 | 151.3 | 309,160 |
| cytomegalovirus infectionSignal | 4,470 | 72.4 | 70.0 | 230,438 |
| product use in unapproved indicationSignal | 7,029 | 5.7 | 5.6 | 27,110 |
| infectionSignal | 3,508 | 4.9 | 4.7 | 10,671 |
| acute kidney injurySignal | 3,099 | 4.1 | 3.9 | 7,083 |
| off label useSignal | 16,486 | 3.8 | 3.7 | 34,500 |
| pneumoniaSignal | 4,405 | 2.7 | 2.6 | 4,786 |
| pyrexiaSignal | 4,594 | 2.7 | 2.6 | 4,735 |
| condition aggravatedSignal | 3,948 | 2.6 | 2.5 | 3,862 |
| diarrhoea | 5,216 | 1.6 | 1.6 | 1,215 |
| drug ineffective | 10,406 | 1.6 | 1.5 | 2,263 |
| vomiting | 3,101 | 1.3 | 1.3 | 228 |
| dyspnoea | 3,084 | 1.1 | 1.0 | 18 |
| fatigue | 3,430 | 0.9 | 0.8 | 67 |
| nausea | 3,309 | 0.8 | 0.8 | 124 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.